pegvorhyaluronidase alfa + cisplatin + gemcitabine + atezolizumab

This combination consists of four drugs: **pegvorhyaluronidase alfa** (a PEGylated recombinant human hyaluronidase that degrades hyaluronan in the tumor extracellular matrix), **cisplatin** (a platinum-based chemotherapeutic that crosslinks DNA), **gemcitabine** (a nucleoside analog inhibitor of DNA synthesis), and **atezolizumab** (a monoclonal antibody targeting PD-L1, used as an immune checkpoint inhibitor). Pegvorhyaluronidase alfa is designed to improve drug delivery by depleting intratumoral hyaluronan, potentially enhancing the effectiveness of accompanying chemotherapies like cisplatin and gemcitabine, and immunotherapy like atezolizumab. This combination is investigated primarily for the treatment of various solid tumors, particularly pancreatic ductal adenocarcinoma and possibly other hyaluronan-high or immunogenic cancers[1][3][7]. Most clinical development around pegvorhyaluronidase alfa in combination has focused on pancreatic cancer and related tumors, but development has been discontinued after phase III studies in most cases due to a lack of survival benefit[4][5].

Other names

pegvorhyaluronidase alfa + cisplatin + gemcitabine + atezolizumab